Moray Medical Secures $3.3M Seed Round to Revolutionize Mitral Valve Repair with Microfluidic Robotics

Moray Medical is thrilled to announce a milestone funding round in which the company raised $3.3 million to further advance its groundbreaking mission to enhance the quality of life for millions suffering from leaky heart valves. This investment will accelerate the development and deployment of Moray’s proprietary microfluidic robotics system, which is designed to empower cardiologists to perform mitral valve clip therapies with unprecedented safety, precision, and cost-effectiveness. The innovative system, featuring a digital user interface, allows for single-handed control of clip placement—a significant enhancement over traditional methods—and leverages microfluidics to ensure fast, intuitive, and accurate catheter navigation. In addition, the compact design and reduced manufacturing costs make it an attractive solution compared to existing manual systems. The infusion of these funds is strategically targeted to simplify the percutaneous delivery of valve therapies, directly benefiting the growing population of patients in need. With the structural heart market rapidly expanding, especially in the areas of Transcatheter Mitral Valve Repair (TMVr) and the multibillion-dollar Transcatheter Edge-to-Edge Repair (TEER) market, Moray Medical is uniquely positioned to capitalize on these trends with its advanced technology. Co-founders Mark Barrish and Phillip Laby bring over 50 years of combined experience in pioneering surgical robotics and core technologies, reinforcing Moray’s capability to lead innovation in this competitive landscape. With this new funding, Moray Medical is not only set to strengthen its technological capabilities but also to extend its reach into markets that can truly transform the lives of patients by offering more accessible and effective cardiac care solutions.